Archive by category | – Brady Huggett

New Bioentrepreneur article

New Bioentrepreneur article

We’ve posted a new article, Shape Shifting, to the Bioentrepreneur site. The piece examines how to mold a company’s pipeline and opportunities, making it most attractive for partnering or buyout. It was written Bob Baltera, CEO of Amira (at the time), and the title refers to the necessity of changing the shape of a company as it progresses. But shape shifting could also refer to the article itself. The process began early this year, after a meeting with Bob at the JP Morgan healthcare conference. The article went through several drafts and took months to put together — long enough  … Read more

Bioentrepreneur article online

We’ve posted a new article on the Bioentrepreneur website, Headwinds into Opportunity, by Prabhavathi Fernandes. The author is CEO, president and founder of Cempra Pharmaceuticals, and she previously helmed DarPharma, Ricerca Biosciences and Small Molecule Therapeutics. She’s also worked at BMS and Abbott. For more on her background, go here.  Read more

Your questions, answered (or at least discussed)

Your questions, answered (or at least discussed)

A Trade Secrets reader recently emailed me to ask if we might supply a post on this question: “How would an entrepreneur or small biotech raise funding, after having biological proof of concept?” I put that to our authors. I received a handful of answers (pasted below), and also a few promises to tackle that question in coming posts. As always, feel free to direct remarks or further questions to the authors in the comments section. David Wilson, whose experience is from China and the US, said: On the surface I have witnessed all types of financing vehicles, from traditional  … Read more

New Bioentrepreneur article

We’ve put a new article on the Bioentrepreneur site, written by Simcha Jong. His piece, Commercializing a disruptive technology, offers perspective and advice to bioentrepreneurs developing new technologies. It is broken loosely into two parts, covering product and platform strategies.  Read more

Boiling Things Down

Boiling Things Down

I haven’t had a chance to mention this yet, but Monday night’s reception at the Newseum was packed, pretty loud and interesting. The most memorable thing for me was the exhibit on Pulitzer Prize winning photographs. The images are haunting. You don’t receive the Pulitzer for pictures of kittens dozing among tulips. Winners included images of an execution in Saigon, Kosovo refugees passing a baby over barbed wire, and the reaction of students amid the Columbine massacre here in the US. Each picture seemed to show either an attempt to end a life, or efforts to protect/save one, so they  … Read more

That Elusive Factor

That Elusive Factor

Day 1 of the BIO convention. The Walter E Washington Convention Center is a huge thing, split into two sections. Panel sessions run on both sides, and the exhibition hall (opening Tuesday) is below ground, spanning some great distance underneath it all. There are hundreds of rooms and people scurrying all over, yet I spent my first hour huddled in a quiet spot along a deserted corridor on the ground floor, talking to an Argentine. He’s working at the interface of science and research, helping Argentina recognize it can not only do routine biotech research, but also produce vaccines, antibodies and diagnostic kits right at home.  Read more

BIO Convention 2011

BIO Convention 2011

I’ll be attending the annual Biotechnology Industry Organization (BIO) Convention next week in Washington, DC. For those readers not familiar, it’s biotech’s largest gathering of execs, insiders and supporters – in peak years, the convention drew more than 20,000 attendees. The total has dipped since then, but it’s expected that more than 15,000 will descend on the capital this year. That throng includes the media – there will be hundreds of members of the press there.  Read more

Protecting the Fortress

We’ve just published a new article on the Bioentrepreneur website, this one actually a reported piece.  We’d been considering an article on the security measures needed for biotechs, in particular startups, for a while now, and after meeting Hamilton Mixon at BIO last year I thought we had a good base for the article.  Read more